402 related articles for article (PubMed ID: 19286191)
1. Expression and clinical significance of CD147 in genitourinary carcinomas.
Han ZD; He HC; Bi XC; Qin WJ; Dai QS; Zou J; Ye YK; Liang YX; Zeng GH; Zhu G; Chen ZN; Zhong WD
J Surg Res; 2010 May; 160(2):260-7. PubMed ID: 19286191
[TBL] [Abstract][Full Text] [Related]
2. Decreased RECK and Increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness.
Wittschieber D; Stenzinger A; Klauschen F; Stephan C; Jung K; Erbersdobler A; Rabien A
Pathobiology; 2011; 78(3):123-31. PubMed ID: 21613799
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic evaluation of immunohistochemical CD147 and MMP-2 expression in differentiated thyroid carcinoma.
Tan H; Ye K; Wang Z; Tang H
Jpn J Clin Oncol; 2008 Aug; 38(8):528-33. PubMed ID: 18664479
[TBL] [Abstract][Full Text] [Related]
4. Increasing expression of extracellular matrix metalloprotease inducer in renal cell carcinoma: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Jin JS; Hsieh DS; Lin YF; Wang JY; Sheu LF; Lee WH
Int J Urol; 2006 May; 13(5):573-80. PubMed ID: 16771728
[TBL] [Abstract][Full Text] [Related]
5. CD147 and VEGF expression in advanced renal cell carcinoma and their prognostic value.
Liang YX; He HC; Han ZD; Bi XC; Dai QS; Ye YK; Qin WJ; Zeng GH; Zhu G; Xu CL; Zhong WD
Cancer Invest; 2009 Aug; 27(7):788-93. PubMed ID: 19548138
[TBL] [Abstract][Full Text] [Related]
6. CD147 expression as a significant prognostic factor in differentiated thyroid carcinoma.
Tan H; Ye K; Wang Z; Tang H
Transl Res; 2008 Sep; 152(3):143-9. PubMed ID: 18774544
[TBL] [Abstract][Full Text] [Related]
7. EMMPRIN expression in tongue squamous cell carcinoma.
Huang Z; Huang H; Li H; Chen W; Pan C
J Oral Pathol Med; 2009 Jul; 38(6):518-23. PubMed ID: 19473445
[TBL] [Abstract][Full Text] [Related]
8. EMMPRIN expression as a prognostic factor in radiotherapy of cervical cancer.
Ju XZ; Yang JM; Zhou XY; Li ZT; Wu XH
Clin Cancer Res; 2008 Jan; 14(2):494-501. PubMed ID: 18223224
[TBL] [Abstract][Full Text] [Related]
9. Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells.
Reimers N; Zafrakas K; Assmann V; Egen C; Riethdorf L; Riethdorf S; Berger J; Ebel S; Jänicke F; Sauter G; Pantel K
Clin Cancer Res; 2004 May; 10(10):3422-8. PubMed ID: 15161697
[TBL] [Abstract][Full Text] [Related]
10. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer.
Als AB; Dyrskjøt L; von der Maase H; Koed K; Mansilla F; Toldbod HE; Jensen JL; Ulhøi BP; Sengeløv L; Jensen KM; Orntoft TF
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4407-14. PubMed ID: 17671123
[TBL] [Abstract][Full Text] [Related]
11. Emmprin, a cell surface inducer of matrix metalloproteinases (MMPs), is expressed in T-cell lymphomas.
Nabeshima K; Suzumiya J; Nagano M; Ohshima K; Toole BP; Tamura K; Iwasaki H; Kikuchi M
J Pathol; 2004 Mar; 202(3):341-51. PubMed ID: 14991900
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of extracellular matrix metalloprotease inducer: immunohistochemical analyses of colorectal tumors and immunocytochemical screening of disseminated tumor cells in bone marrow from patients with gastrointestinal cancer.
Buergy D; Fuchs T; Kambakamba P; Mudduluru G; Maurer G; Post S; Tang Y; Nakada MT; Yan L; Allgayer H
Cancer; 2009 Oct; 115(20):4667-78. PubMed ID: 19569245
[TBL] [Abstract][Full Text] [Related]
13. Association of extracellular matrix metalloproteinase inducer in endometrial carcinoma with patient outcomes and clinicopathogenesis using monoclonal antibody 12C3.
Ueda K; Yamada K; Urashima M; Ishibashi Y; Shirai M; Nikaido T; Takahashi H; Okamoto A; Saito M; Yasuda M; Ohkawa K; Tanaka T
Oncol Rep; 2007 Apr; 17(4):731-5. PubMed ID: 17342307
[TBL] [Abstract][Full Text] [Related]
14. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer.
Zhong WD; Han ZD; He HC; Bi XC; Dai QS; Zhu G; Ye YK; Liang YX; Qin WJ; Zhang Z; Zeng GH; Chen ZN
Oncology; 2008; 75(3-4):230-6. PubMed ID: 18852494
[TBL] [Abstract][Full Text] [Related]
15. Extracellular matrix metalloprotease inducer stimulates fibroblast-mediated tumor growth in vivo.
Rosenthal EL; Vidrine DM; Zhang W
Laryngoscope; 2006 Jul; 116(7):1086-92. PubMed ID: 16826041
[TBL] [Abstract][Full Text] [Related]
16. Extracellular matrix metalloproteinase inducer expression has an impact on survival in human bladder cancer.
Zhong WD; Chen QB; Ye YK; Han ZD; Bi XC; Dai QS; Liang YX; Zeng GH; Wang YS; Zhu G; Chen ZN; He HC
Cancer Epidemiol; 2010 Aug; 34(4):478-82. PubMed ID: 20483678
[TBL] [Abstract][Full Text] [Related]
17. Expression of CD147 as a significantly unfavorable prognostic factor in hepatocellular carcinoma.
Zhang Q; Zhou J; Ku XM; Chen XG; Zhang L; Xu J; Chen GS; Li Q; Qian F; Tian R; Wen N; Chen ZN
Eur J Cancer Prev; 2007 Jun; 16(3):196-202. PubMed ID: 17415090
[TBL] [Abstract][Full Text] [Related]
18. Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN.
Tang Y; Kesavan P; Nakada MT; Yan L
Mol Cancer Res; 2004 Feb; 2(2):73-80. PubMed ID: 14985463
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to cisplatin in laryngeal carcinoma Hep2 cells.
Zhu C; Pan Y; He B; Wang B; Xu Y; Qu L; Bao Q; Tian F; Wang S
Oncol Rep; 2011 Feb; 25(2):425-32. PubMed ID: 21165561
[TBL] [Abstract][Full Text] [Related]
20. High incidence of extracellular matrix metalloproteinase inducer expression in non-small cell lung cancers. Association with clinicopathological parameters.
Hakuma N; Betsuyaku T; Kinoshita I; Itoh T; Kaga K; Kondo S; Nishimura M; Dosaka-Akita H
Oncology; 2007; 72(3-4):197-204. PubMed ID: 18160808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
